Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.34% | -75.77% | -73.78% | -74.28% | -67.11% |
| Total Depreciation and Amortization | 9.32% | 8.95% | 4.89% | 0.84% | 4.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 998.73% | 113.85% | 108.73% | 105.97% | 101.58% |
| Change in Net Operating Assets | 85.61% | 248.33% | -381.61% | 159.62% | -4,475.61% |
| Cash from Operations | 68.85% | 116.42% | 55.06% | 194.15% | 26.09% |
| Capital Expenditure | -37.72% | -38.50% | -10.70% | -3.09% | 26.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 88.70% | 96.83% | 96.69% | -- | 58.44% |
| Divestitures | -98.92% | -99.46% | -99.46% | -99.46% | 0.00% |
| Other Investing Activities | 89.87% | 86.05% | 85.07% | 88.29% | -29,557.24% |
| Cash from Investing | 32.13% | -144.75% | -138.16% | -130.82% | -137.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.38% | 11.46% | 15.42% | -3.01% | -7.44% |
| Repurchase of Common Stock | 11.53% | 12.23% | 24.61% | 22.94% | 46.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.74% | -2,736.90% | -10,650.00% | -7,561.29% | -19,425.00% |
| Cash from Financing | 38.51% | -4.30% | 11.72% | 2.67% | 35.65% |
| Foreign Exchange rate Adjustments | 88.89% | 130.33% | -268.75% | -216.06% | 117.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.24% | -123.30% | -136.53% | -106.24% | -143.56% |